The proportion of racial/ethnic minorities receiving ventricular assist devices (VADs) has previously been less than expected. It is unclear if trends have changed since the broadening of access to insurance in 2014 and the rapid adoption of VAD technology.
H
eart failure disproportionately affects racial/ethnic minorities, particularly African-Americans. 1 Among patients with advanced heart failure, ventricular assist device (VAD) extend life expectancy and improve quality of life. 2 However, historically racial/ ethnic minorities received <1/3 of VADs in the United States 3 despite representing 40% of all heart failure hospitalizations and having similar rates of survival compared with whites post-VAD. 4, 5 The distribution declines further among African-American women, who have the highest prevalence of heart failure compared with all other racial/ethnic groups and sexes. 1 African-Americans and Hispanics are at higher risk for developing heart failure at young ages. 1 AfricanAmericans have 2-to 3-fold higher rates of heart failure compared with whites before the age of 75 years. 1 Historically, half of all VADs are implanted in patients aged 60 to 79 years. It is unclear whether racial/ethnic disparities are present across age groups. 3 The factors that contribute to disparate racial/ethnic distribution are complex but may be accounted for by the higher proportion of underinsured racial/ethnic minorities. 6 Insurance is a prerequisite for VAD implantation. 7 The broadening of public insurance has been associated with reduced racial disparities in heart transplant listings 6 and may expand to VADs. In addition, there has been a rapid rise in VAD implantations nationwide 8 and increased public awareness of this technology. 9 It is unclear whether racial/ethnic disparities have changed.
Using the Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS) registry and US Census, we sought to evaluate racial/ethnic per capita trends in receipt of VADs by sex and age. We hypothesized that temporal changes in the census-adjusted rate of receipt of VADs would be higher for racial/ethnic minorities than whites, independent of sex and age.
METHODS

Data Source
The INTERMACS registry collects quarterly data on patients receiving mechanically assisted devices for heart failure. 10 Prior to 2014, the Centers for Medicare and Medicaid Services required all implanting centers to participate in INTERMACS. 11 Since that time, the number of centers participating in INTERMACS has increased. 10 Participating centers are incentivized through receipt of individualized outcomes and quality of care data. Each center obtains informed consent from individual patients and institutional review board approval. To maintain good standing within INTERMACS, centers must provide complete data at regular intervals, including demographics and comorbidities. 10 Race/ethnicity are reported by individual centers. Insurance data are not recorded but required for implantation. Researchers are blinded to center name and location. The National Heart, Lung, and Blood Institute provide oversight to data collection. This study was approved by the INTERMACS Data Access, Analysis, and Publications Committee. The data, analytic methods, and study materials are available to other researchers for the purposes of reproducing the results or replicating the procedure on approval of application to the INTERMACS Data Access, Analysis, and Publications Committee.
Study Cohort
Inclusion criteria comprised adults aged ≥18 years who received a VAD at a participating INTERMACS registry center from 2012 to 2015. Patients with a listed race of African-American, Asian, or white or ethnicity of Hispanic were included. Patients were characterized as non-Hispanic white (white), non-Hispanic AfricanAmerican (African-American), Hispanic, and non-Hispanic Asian (Asian). Other races were excluded because of low representation (n=517). The final cohort included 10 795 patients.
Outcomes of Interest
The primary outcome was the annual census-adjusted rate of VAD implantation. The number of patients living with advanced heart failure in the United States is unknown and could not be used in the rate denominator. Given variation in racial/ethnic US population by time, the annual projected US Census Bureau Estimates for 2012 to 2015 were used in the rate denominator according to race/ethnicity, sex, and age group. This method has been established for demonstrating racial/ethnic differences in rate of receipt of advanced therapies elsewhere. 6 
Statistical Analysis
Patient characteristics were compared by race/ethnicity using χ 
WHAT IS NEW?
• From 2012 to 2015, the annual census-adjusted rate of ventricular assist devices (VADs) implantation increased in African-Americans but not among other racial/ethnic groups. • The change in rate was higher among AfricanAmerican men than women. No differences by sex were seen among other racial/ethnic groups.
• Changes in rate varied according to age group. The change in rate of VAD implant was higher among middle-aged African-Americans and Asians relative to older and younger age groups. No differences by age group were seen among other racial/ ethnic groups.
WHAT ARE THE CLINICAL IMPLICATIONS?
• This study demonstrates that per capita, disparities in receipt of VADs seem to be decreasing among African-Americans who have the highest rates of heart failure. However, racial/ethnic differences in referral rates and approval rates for VADs are unknown. Further investigation should address racial/ethnic and sex variability in the clinical decision-making process for VADs. census-adjusted rate of VAD implantation to assess racial/ethnic trends by time. Monthly implantation dates were not available. From 2012 to 2015, the rate of change in VAD implantation was performed within each racial/ethnic group and stratified by sex and age group. Analyses were performed using SAS, version 9.4 (SAS Institute, Inc, Cary, NC) and R statistical software (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics
From 2012 to 2015, 10 795 patients (white, 67.4%; African-American, 24.8%; Hispanic, 6.3%; Asian 1.5%) received a VAD implantation ( 
Outcomes
In 2012, the estimated annual census-adjusted rate of VAD implantation per 100 000 was 1.09 (95% confi- Other racial/ethnic groups had no significant changes in the rate of VAD implantation by sex.
Stratified by age group, the baseline rate of VAD implantation trended toward higher rates with each successive decade until age 70 years, after which rates declined in each racial/ethnic group (Table 2; Figure C) 
DISCUSSION
In our study of the national INTERMACS database, VAD implantation rates increased significantly among AfricanAmericans but not among other racial/ethnic groups from 2012 to 2015. When stratified by sex, a rate increase was observed in both African-American men and women, with the greatest increase observed in African-American men. When stratified by age group, rates increased among middle-aged African-Americans and Asians. The increased trend in VAD implantation rates among AfricanAmericans is an important observation because AfricanAmericans consistently have the highest rates of heart failure and highest mortality secondary to heart failure. 1 Insurance is required for VAD implantation. 7 AfricanAmericans have a high proportion of underinsurance, 12 and the broadening of access to insurance during the period of study may have contributed to our findings. Similar patterns have been observed in heart transplants, which also require insurance, over the same time period. 6 From 2012 to 2015, an increase in heart transplant listings in African-Americans was associated with the Affordable Care Act Medicaid Expansion. 6 However, the INTERMACS data set does not provide insurance type, month of implantation, or implantation center location granularity. Therefore, it is difficult to infer that the changes in rate are all or in part because of insurance.
Additional considerations for racial differences in VAD implantation include an increase in the number of destination VAD centers during the study period. The bridge to transplant strategy occurs primarily at heart transplant centers, which have been stagnant in number. 13 Since 2012, >20 additional destination therapy VAD centers have received Centers for Medicare and Medicaid Services approval.
14 Most VAD centers are located in metropolitan settings with larger proportions of African-American residents.
14 In this study, destination VAD was the strategy for a greater proportion of African-American and white patients than Hispanic and Asian patients. An additional contributor to the observed changes in VAD implant rates may be increased public awareness of VAD technology after the publicity resulting from VAD implantation in a public figure. 9 However, no data on racial/ethnic preferences for advanced therapies currently exist. Increased awareness would not be expected to differ by race or ethnicity, but awareness may contribute to the overall upwards trend of total VAD implantations across the United States Women received fewer VADs than men, similar to heart transplant where women receive less than a quarter of heart transplants. 6, 15 It is posited that this is †Significant subgroup interactions of sex×time for African-Americans P=0.004, age group×time for African-Americans P<0.01, and age group×time Asians P=0.02; and 95% confidence intervals are in parentheses.
related to the lower incidence of systolic heart failure in women 1 and higher prevalence of heart failure with preserved ejection fraction, 1, 7 which is not an indication for VAD implantation. However, this rationale for disparities breaks down when considering the interaction of race/ethnicity. Heart failure with reduced ejection fraction is the most common pathogenesis of heart failure admissions for African-American women, 16 who have the highest rate of heart failure among women, followed by white, Hispanic, and Asian women. 1 In addition, before the age of 75 years, rates of heart failure are higher in African-American women than either white men or women. 1 In our study, the rate of VAD implantation increased significantly among African-American women, with rates higher than white women but lower than white men. Many factors likely contribute to these findings by age and sex. Further study is needed to understand the health- care provider and patient decision-making process for VAD implantation.
By age, VAD implantation rates mimicked rates of heart failure, increasing with successive decades of life. 1 Within racial/ethnic groups, rates increased among African-Americans aged 40 to 69 years and Asians aged 50 to 59 years. This follows an expected pattern for African-Americans because they develop heart failure at younger ages. 1 The pattern is less clear for Asians who have the lowest prevalence of heart failure. 1 The under-reporting of Asian race, heterogeneity of the Asian population, and variability of cardiovascular risk factors among the different Asian ethnicities likely contribute and require further study. 17 A new trend developed among the age group of 70+ years. Beyond the seventh decade of life, implant rates declined across all racial/ethnic groups, particularly among African-Americans. This may reflect a hesitancy to provide advanced therapies to those 70+ years of age. As observed in heart transplants, patients in their seventh decade are often declined VAD therapy because of increased comorbidities, frailty, and lower life expectancy because of age alone. 18 As the general population continues to age, the advanced heart failure guidelines for older patients may require additional consideration. 7, 18 Investigation of the racial differences in VAD implantation in patient >70 years is warranted.
The understanding of racial disparities in VAD implantation is incomplete. We found that per capita VAD implantation rates were the highest among African-Americans, followed by whites, Hispanics, and Asians. Although the per capita rate in African-Americans was double the rate of whites, this rate was lower than expected based on differences in heart failure incidence by race. In 2012, a per capita rate of 2.01 in African-Americans translates to 514 VADs and a per capita rate of 1.09 in whites translates to 1621 VADs. Annual heart failure rates are 2× to 3× higher in African-Americans than whites before age 75 years, 1 and the majority of VADs are implanted in this population. 3 Adjusted for age, the 2012 heart failure discharge rate per capita of 100 000 has been reported as 875 in African-American men, 376 in white men, 663 in African-American women, and 270 in white women. 19 Thus, this suggests there is a racial disparity. Yet, several factors reduce the ability to clarify disparities. Specifically, it is unknown nationally who has advanced heart failure, who is not getting an appropriate referral for VAD evaluation, and who is not being approved for VADs. It is known that African-Americans with heart failure are less likely to receive care by cardiologists than whites and that racial biases inhibit general referral of African-Americans to cardiologists. 20, 21 Comprehensive identification of the at-risk US advanced heart failure population and identification of racial/ethnic and sex variation in the referral and evaluation for advanced therapies are needed to achieve health equity. Specifically, future work should investigate (1) whether clinical decision making for allocation of advanced therapies differ by race/ethnicity and sex, and (2) whether patient preferences for advanced therapies differ by race/ethnicity and sex.
Study Limitations
This study has several limitations. First, the denominator of the rate included the US census population, which prohibited adjustment for patient characteristics. However, results were stratified and adjusted for by age and sex, which may be the most pertinent characteristics. The best denominator, all patients with advanced heart failure, is not currently available, and collection of this data should be an objective of future national registries. Second, insurance status was unknown. We do know that carrying insurance is a guideline requirement for VAD implantation. 7 Therefore, it is likely that all patients had some form of health insurance, but we do not know about otherwise eligible patients who had insufficient insurance to receive a VAD in this time period. Third, this data set lacks information on patients referred for VAD evaluation and declined for implantation. The clinical decision-making processes leading to referral and approval of VADs may contribute to racial/ethnic and sex disparities, and these processes require investigation. Last, INTERMACS was not a required registry for VAD implantation after 2014. 10 Although all VAD implants in the United States may have not been captured, the continued increase in center participation with INTERMACS suggests that the number of missing patients is likely trivial in the data set used for this analysis.
Conclusions
From 2012 to 2015, VAD implantation rates increased significantly among African-Americans, particularly among middle-aged African-American men. Other races/ethnicities and subgroups by sex and age had no changes in the rate of VAD implantation during this time period with the exception of middle-aged Asians. This suggests that racial disparities may be declining among African-Americans, but further investigation is needed to reduce racial/ethnic disparities observed by sex and age.
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